Strides Pharma to spin off CDMO, soft gelatin business into new entity
Bengaluru: India's Strides Pharma Science has said it would spin off its contract development and manufacturing organisation (CDMO) and soft gelatin business into a new entity which would list in the next 12-16 months.The new company, known as "OneSource", will have more than 1,200 employees and is expected to deliver revenue worth between $180 million - $200 million in fiscal 2025.Read...
Bengaluru: India's Strides Pharma Science has said it would spin off its contract development and manufacturing organisation (CDMO) and soft gelatin business into a new entity which would list in the next 12-16 months.
The new company, known as "OneSource", will have more than 1,200 employees and is expected to deliver revenue worth between $180 million - $200 million in fiscal 2025.
It is also targeting earnings before interest, taxes, depreciation and amortisation, or EBITDA margin of nearly 30%, which is expected to improve to over 35% from FY26 onwards.
Shareholders of Strides would hold 44% value in OneSource and will receive one share of OneSource for every two shares held in Strides, valuing the shares of Strides at 364 rupees apiece.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd